Compared side by side
Liraglutide vs exenatide: how they differ
The short answer
Both are GLP-1 receptor agonists given as frequent shots: exenatide, a copy of exendin-4 from Gila monster venom, lasts about 2.4 hours and is taken before the two main meals, and liraglutide, semaglutide’s predecessor, lasts about 13 hours and is taken once a day. Exenatide was FDA-approved in 2005, as Byetta, for blood sugar control in type 2 diabetes, and its US products are being discontinued; liraglutide is FDA-approved for type 2 diabetes as Victoza and for weight management as Saxenda. Commonly reported: a smaller appetite and nausea in the first weeks of exenatide, and on liraglutide appetite dropping and meals ending sooner, with nausea during the climb to 3 mg.
Side by side
| Compared | Liraglutide | Exenatide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Victoza, Saxenda, Liraglutide injection | Byetta, Exendin-4, AC2993 |
| What it is | The predecessor to semaglutide: a GLP-1 receptor agonist that reduces appetite and improves blood sugar control, given as a daily injection rather than weekly. | The first GLP-1 drug, made from a peptide found in Gila monster venom, approved in 2005 as Byetta for type 2 diabetes: a shot before breakfast and dinner that lowers blood sugar after meals. |
| How it works | GLP-1 receptor agonist and predecessor to semaglutide. Stimulates insulin secretion, reduces glucagon, slows gastric emptying, and reduces appetite. Shorter half-life than semaglutide requiring daily dosing. FDA approved for type 2 diabetes (Victoza) and obesity (Saxenda). The labels step the dose up from 0.6 mg to minimize GI side effects. | The first GLP-1 receptor agonist approved: a synthetic copy of exendin-4, a 39-amino-acid peptide first found in the venom of the Gila monster, whose sequence partly overlaps human GLP-1. It releases insulin when glucose is high, lowers glucagon and slows stomach emptying, and it reduces food intake. It is cleared by the kidneys with a half-life of about 2.4 hours, so the original form (Byetta) is a shot before the two main meals of the day. FDA-approved in 2005 for type 2 diabetes in adults; it is not approved for weight management, and every US exenatide product is now listed as discontinued. |
| Commonly reported | Appetite drops and meals end sooner, though less dramatically than on semaglutide or tirzepatide, with nausea during the climb to 3 mg. FDA-approved for diabetes (Victoza) and obesity (Saxenda), with one of the longest track records of any GLP-1 drug. | A smaller appetite and nausea in the first weeks, easing for most people with time. Every US exenatide product, including the weekly Bydureon BCise, is now listed by the FDA as discontinued. |
| Studied range | FDA label: 0.6–3 mg, starting dose 0.6 mg. | FDA label: 5–10 mcg, starting dose 5 mcg. |
| How often | Daily SubQ | Twice daily SubQ, before meals |
| Half-life | ~13 hours | ~2.4 hours (FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for daily use. Community uses continuously or until goal reached. | FDA-approved for ongoing use in type 2 diabetes; the label's trials ran 16 to 30 weeks, with open-label extensions to 52 weeks. The once-weekly extended-release form (Bydureon, later Bydureon BCise) was studied for a median of 3.2 years in EXSCEL. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, vomiting, diarrhea, constipation, pancreatitis risk, thyroid C-cell tumor risk (animal data) | Nausea, vomiting, diarrhea, feeling jittery, dizziness, headache, indigestion, low blood sugar (with a sulfonylurea or insulin) |
- Category
- LiraglutideMetabolic & GLP-1
- ExenatideMetabolic & GLP-1
- Also known as
- LiraglutideVictoza, Saxenda, Liraglutide injection
- ExenatideByetta, Exendin-4, AC2993
- What it is
- LiraglutideThe predecessor to semaglutide: a GLP-1 receptor agonist that reduces appetite and improves blood sugar control, given as a daily injection rather than weekly.
- ExenatideThe first GLP-1 drug, made from a peptide found in Gila monster venom, approved in 2005 as Byetta for type 2 diabetes: a shot before breakfast and dinner that lowers blood sugar after meals.
- How it works
- LiraglutideGLP-1 receptor agonist and predecessor to semaglutide. Stimulates insulin secretion, reduces glucagon, slows gastric emptying, and reduces appetite. Shorter half-life than semaglutide requiring daily dosing. FDA approved for type 2 diabetes (Victoza) and obesity (Saxenda). The labels step the dose up from 0.6 mg to minimize GI side effects.
- ExenatideThe first GLP-1 receptor agonist approved: a synthetic copy of exendin-4, a 39-amino-acid peptide first found in the venom of the Gila monster, whose sequence partly overlaps human GLP-1. It releases insulin when glucose is high, lowers glucagon and slows stomach emptying, and it reduces food intake. It is cleared by the kidneys with a half-life of about 2.4 hours, so the original form (Byetta) is a shot before the two main meals of the day. FDA-approved in 2005 for type 2 diabetes in adults; it is not approved for weight management, and every US exenatide product is now listed as discontinued.
- Commonly reported
- LiraglutideAppetite drops and meals end sooner, though less dramatically than on semaglutide or tirzepatide, with nausea during the climb to 3 mg. FDA-approved for diabetes (Victoza) and obesity (Saxenda), with one of the longest track records of any GLP-1 drug.
- ExenatideA smaller appetite and nausea in the first weeks, easing for most people with time. Every US exenatide product, including the weekly Bydureon BCise, is now listed by the FDA as discontinued.
- Studied range
- LiraglutideFDA label: 0.6–3 mg, starting dose 0.6 mg.
- ExenatideFDA label: 5–10 mcg, starting dose 5 mcg.
- How often
- LiraglutideDaily SubQ
- ExenatideTwice daily SubQ, before meals
- Half-life
- Liraglutide~13 hours
- Exenatide~2.4 hours (FDA label)
- Route
- LiraglutideSubQ injection
- ExenatideSubQ injection
- Typical run
- LiraglutideFDA-approved for daily use. Community uses continuously or until goal reached.
- ExenatideFDA-approved for ongoing use in type 2 diabetes; the label's trials ran 16 to 30 weeks, with open-label extensions to 52 weeks. The once-weekly extended-release form (Bydureon, later Bydureon BCise) was studied for a median of 3.2 years in EXSCEL.
- Evidence
- LiraglutideEstablished: clinical trials or FDA-approved use exists
- ExenatideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- LiraglutideNausea, vomiting, diarrhea, constipation, pancreatitis risk, thyroid C-cell tumor risk (animal data)
- ExenatideNausea, vomiting, diarrhea, feeling jittery, dizziness, headache, indigestion, low blood sugar (with a sulfonylurea or insulin)
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Liraglutide
- Day 1–14 · 0.6 mg Starting dose — GI is the main thing
- Day 14–42 Titrating up — appetite really drops
- Day 42–168 Steady loss at target dose
- Day 168–365 Maintenance and long game
Exenatide
- Day 1–30 · 5 mcg The 5 mcg start, before two meals
- Day 1–60 Why the shot comes before the meal
- Day 31–180 · 10 mcg 10 mcg, the full dose
- Day 181+ A medicine the market moved past
Questions people ask
How long do liraglutide and exenatide last?
The half-life of liraglutide is ~13 hours. The half-life of exenatide is ~2.4 hours (FDA label).
How often are liraglutide and exenatide taken?
Liraglutide: daily SubQ. Route: SubQ injection. Exenatide: twice daily SubQ, before meals. Route: SubQ injection.
How are liraglutide and exenatide dosed in research?
The FDA label range for liraglutide is 0.6–3 mg, with a 0.6 mg starting dose. The FDA label range for exenatide is 5–10 mcg, with a 5 mcg starting dose.
What are the common side effects of liraglutide and exenatide?
For liraglutide, the library lists: nausea, vomiting, diarrhea, constipation, pancreatitis risk, thyroid C-cell tumor risk (animal data). For exenatide: nausea, vomiting, diarrhea, feeling jittery, dizziness, headache, indigestion, low blood sugar (with a sulfonylurea or insulin).